Proper Résumés - Résumés that stand out and breakthrough applicant tracking systems. | Facebook
SEC Filing | Sage Therapeutics, Inc.
Sage surges after depression drug gets rapid path to approval - PMLiVE
sage-10k_20181231.htm
Zuranolone, a breakthrough postpartum depression treatment, was just approved by the FDA. The fast-acting pill can improve symptoms in 3 days
Sage Announces Results of FDA Breakthrough Therapy Meeting – ISPE Boston
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Biogen signs $1.5bn depression drug deal with Sage Therapeutics
Sage Therapeutics Gets FDA Breakthrough Therapy Designation for Major Depressive Disorder Drug - Equities News
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Business Wire
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
FDA Provides Expedited Path Forward For Sage's Depression Treatment SAGE-217 | BioSpace
Sage advice: psychiatric drug development is tough | Evaluate
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Sage Therapeutics surges 70% after depression drug breakthrough
Biogen signs deal with Sage to develop depression, tremor therapies
sage-10k_20191231.htm
Zulresso: the world's first post-partum depression drug - Pharmaceutical Technology
Zuranolone: Treatment Of Major Depression (MDD) And Postpartum Depression (PDD)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
SY Investing on X: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Rx Product News: April 2023
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
